Twist Bioscience Stock Hits Day High with 7.1% Surge, Outperforming S&P 500

Twist Bioscience Corp., a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable surge in its stock price, gaining 7.1% on May 26, 2026. The stock reached an intraday high of USD 65.59, reflecting strong performance metrics compared to the broader market. Over the past week, Twist Bioscience has outperformed the S&P 500 with a remarkable 31.05% increase, while its one-year performance stands at an impressive 129.55%, significantly surpassing the S&P 500's 29.58%. Despite its recent gains, the company has faced challenges, with a reported operating cash flow of USD -51.01 million and a net profit of USD -57.65 million for the half-year. The return on capital employed (ROCE) is currently at -16.79%. However, the stock's high institutional holdings at 100% indicate strong backing from investors with substantial resources to analyze the company's fundamentals. Overall, Twist Bioscience's recent performance highlights its volatility and potential within the biotechnology landscape, as it continues to navigate the complexities of its financial metrics.